In a murine colorectal cancer model, the clinically approved ARB (candesartan) was reported to inhibit angiotensin II signaling, thereby impairing the suppressive TME and inducing infiltration of CD8+ T cells to enhance the anti-tumor response to ICI therapy [143]. This evidence concerns the gene CD8A and neoplasm.